NO20064985L - Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer - Google Patents
Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommerInfo
- Publication number
- NO20064985L NO20064985L NO20064985A NO20064985A NO20064985L NO 20064985 L NO20064985 L NO 20064985L NO 20064985 A NO20064985 A NO 20064985A NO 20064985 A NO20064985 A NO 20064985A NO 20064985 L NO20064985 L NO 20064985L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- diagnostics
- activated receptor
- peroxisome proliferator
- demyelinating diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55853304P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/010371 WO2005097098A2 (en) | 2004-04-01 | 2005-03-29 | Use of ppr delta agonists for treating demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064985L true NO20064985L (no) | 2006-10-31 |
Family
ID=34977094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064985A NO20064985L (no) | 2004-04-01 | 2006-10-31 | Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070149580A1 (enExample) |
| EP (1) | EP1737440A2 (enExample) |
| JP (1) | JP2007530703A (enExample) |
| KR (1) | KR20060134191A (enExample) |
| CN (1) | CN1950077A (enExample) |
| AU (1) | AU2005231358A1 (enExample) |
| BR (1) | BRPI0509540A (enExample) |
| CA (1) | CA2561159A1 (enExample) |
| IL (1) | IL178165A0 (enExample) |
| MA (1) | MA28561B1 (enExample) |
| MX (1) | MXPA06011218A (enExample) |
| NO (1) | NO20064985L (enExample) |
| RU (1) | RU2006138495A (enExample) |
| SG (1) | SG138623A1 (enExample) |
| WO (1) | WO2005097098A2 (enExample) |
| ZA (1) | ZA200607850B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| EP2298742B1 (en) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy acetic acids as PPAR delta activators |
| CN101336113B (zh) * | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
| EP2386540A1 (en) | 2005-12-22 | 2011-11-16 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| CA2727373A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US8716317B2 (en) | 2008-06-09 | 2014-05-06 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| US20130117868A1 (en) | 2009-12-17 | 2013-05-09 | Sanofi | Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging |
| DK2675893T3 (en) * | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
| WO2004093910A1 (ja) * | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
-
2005
- 2005-03-29 JP JP2007506442A patent/JP2007530703A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509540-9A patent/BRPI0509540A/pt not_active IP Right Cessation
- 2005-03-29 RU RU2006138495/14A patent/RU2006138495A/ru not_active Application Discontinuation
- 2005-03-29 WO PCT/US2005/010371 patent/WO2005097098A2/en not_active Ceased
- 2005-03-29 CA CA002561159A patent/CA2561159A1/en not_active Abandoned
- 2005-03-29 SG SG200800123-2A patent/SG138623A1/en unknown
- 2005-03-29 MX MXPA06011218A patent/MXPA06011218A/es not_active Application Discontinuation
- 2005-03-29 EP EP05729215A patent/EP1737440A2/en not_active Withdrawn
- 2005-03-29 CN CNA2005800148506A patent/CN1950077A/zh active Pending
- 2005-03-29 KR KR1020067022955A patent/KR20060134191A/ko not_active Withdrawn
- 2005-03-29 AU AU2005231358A patent/AU2005231358A1/en not_active Abandoned
-
2006
- 2006-09-18 IL IL178165A patent/IL178165A0/en unknown
- 2006-09-19 ZA ZA200607850A patent/ZA200607850B/xx unknown
- 2006-09-26 US US11/535,240 patent/US20070149580A1/en not_active Abandoned
- 2006-10-31 MA MA29427A patent/MA28561B1/fr unknown
- 2006-10-31 NO NO20064985A patent/NO20064985L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097098A2 (en) | 2005-10-20 |
| KR20060134191A (ko) | 2006-12-27 |
| CN1950077A (zh) | 2007-04-18 |
| IL178165A0 (en) | 2008-03-20 |
| US20070149580A1 (en) | 2007-06-28 |
| SG138623A1 (en) | 2008-01-28 |
| BRPI0509540A (pt) | 2007-09-18 |
| CA2561159A1 (en) | 2005-10-20 |
| MXPA06011218A (es) | 2007-01-16 |
| JP2007530703A (ja) | 2007-11-01 |
| WO2005097098A3 (en) | 2005-12-22 |
| MA28561B1 (fr) | 2007-04-03 |
| AU2005231358A1 (en) | 2005-10-20 |
| ZA200607850B (en) | 2008-10-29 |
| RU2006138495A (ru) | 2008-05-10 |
| EP1737440A2 (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20064985L (no) | Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer | |
| Hatzifotis et al. | Hydrofluoric acid burns | |
| US9039718B2 (en) | Method and device for treating an ocular disorder | |
| US20140052164A1 (en) | Instrument for treating an ocular disorder | |
| US20140214062A1 (en) | Method and device for treating an ocular disorder | |
| Kuo et al. | Ultrasound-guided perineural injection with platelet-rich plasma improved the neurophysiological parameters of carpal tunnel syndrome: A case report | |
| EP1948161A4 (en) | METHOD FOR PREVENTING AND TREATING PPAR-MEDIATED CONDITIONS WITH MACELIGNAN | |
| Can | Dupuytren’s contracture | |
| Xu et al. | Comparison between the efficacy of spinal cord stimulation and of endovascular revascularization in the treatment of diabetic foot ulcers: a retrospective observational study | |
| Gajdos et al. | Is an implant removal after dorsal plating of distal radius fracture always needed? | |
| Bigorre et al. | Lateral epicondylitis treatment by extensor carpi radialis fasciotomy and radial nerve decompression: is outcome influenced by the occupational disease compensation aspect? | |
| Zhang et al. | Study on the effect, safety, prognosis quality and application value of extracorporeal shock wave based neural activity in carpal tunnel syndrome patients | |
| Zeinali et al. | Comparison of the effects of kinesio taping to local injection of methyl prednisolone in treating brachial biceps tendonitis | |
| Lee et al. | Functional improvement and scar impact of electromyography (EMG)-driven robotic training on nerve damage and hypertrophic scars in hands that underwent skin grafting after burns: a prospective, randomized, single-blinded study | |
| SATYANARAYANA et al. | OPEN REDUCTION AND INTERNAL FIXATION WITH PLATING VERSUS EXTERNAL FIXATOR IN DISTAL END RADIUS FRACTURES: A COMPARATIVE STUDY | |
| RU2408322C1 (ru) | Способ смещения нижней челюсти вниз для увеличения верхнего суставного пространства височно-нижнечелюстного сустава перед выполнением пункции сустава | |
| Poonsuk et al. | Comparing Treatment Efficacy of Court-type Traditional Thai Massage, Elastic Taping, and Stretching for Plantar Fasciitis: A Three-Armed Randomized Controlled Trial | |
| Ramana et al. | Efficacy of Therapeutic Ultrasound and Therapeutic Laser Along with Myofascial Release in Reducing Pain and Improving Hand Grip for People with Lateral Epicondylitis. | |
| Shivachev et al. | Oncology Rehabilitation-an alternative to breast cancer treatment | |
| RU2366398C1 (ru) | Способ устранения болевого синдрома в ягодичной области | |
| CN107213224A (zh) | 一种舒筋活血酒 | |
| Sohn et al. | 154 Anti-inflammatory peptide alleviates dermatitis in an Atopic dermatitis mouse model | |
| BRPI0414564A (pt) | derivados de 2-alcilideno-19-nor-vitamina d para tratamento de fraqueza, lesão muscular ou sarcopenia | |
| RU2221612C1 (ru) | Способ профилактики заболеваний суставов верхних конечностей профессиональной этиологии | |
| Korkmaz et al. | Ultrasound-guided hydrodissection to entrapped median nerve after electric shock: A case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |